Penumbra director granted 589 RSUs

Grewal Harpreet reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Grewal Harpreet reported acquisition or exercise transactions in this Form 4 filing.

Penumbra director Harpreet Grewal received a grant of 589 shares of common stock in the form of restricted stock units at no cost. The RSUs vest in four equal parts on March 31, June 30, September 30 and December 31 2026, if he continues serving as a director.

If the closing of the previously signed merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs will fully vest at that closing, again subject to his continued service. After this award, he directly holds 8,819 Penumbra shares, with a portion still subject to vesting.

Insider Trade Summary

Grant/Award: 589 shares

Grant/Award 1 txn

Insider Grewal Harpreet

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	589	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,819 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units (RSUs) vest as to 1/4 on each of March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to Mr. Grewal's continued service as director through such dates. Notwithstanding the foregoing, if the Closing (as defined in that certain Agreement and Plan of Merger, dated as of January 14, 2026, among the Issuer, Boston Scientific Corporation, a Delaware corporation, and Pinehurst Merger Sub, Inc., a Delaware corporation) occurs, any of the RSUs that remain unvested will fully vest on the Closing, subject to Mr. Grewal's continued service as director through such date.
2. F2. A portion of these shares is subject to vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Penumbra (PEN) report for Harpreet Grewal?

Penumbra reported that director Harpreet Grewal received a grant of 589 restricted stock units, representing common stock, at no cost. These units vest over 2026, increasing his direct holdings to 8,819 shares, some of which remain subject to vesting conditions.

How many Penumbra (PEN) shares does Harpreet Grewal hold after this Form 4?

After the reported transaction, Harpreet Grewal directly holds 8,819 Penumbra common shares. This total includes the newly granted 589 restricted stock units, of which a portion is unvested and will vest over time subject to his continued board service.

What is the vesting schedule for Harpreet Grewal’s new Penumbra (PEN) RSUs?

The 589 restricted stock units vest in four equal installments on March 31, June 30, September 30 and December 31 2026. Each vesting date is contingent on Harpreet Grewal continuing to serve as a Penumbra director through the respective vesting date.

How is the Penumbra (PEN) merger with Boston Scientific referenced in this Form 4?

The filing notes that if the closing of the merger among Penumbra, Boston Scientific Corporation and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs will fully vest at that closing, provided Harpreet Grewal continues to serve as a director through the closing date.

Did Harpreet Grewal pay anything for the 589 Penumbra (PEN) RSUs?

No cash consideration was paid for the 589 restricted stock units; the transaction price per share is reported as 0.0000. This indicates the units were granted as equity-based compensation to Harpreet Grewal in his role as a Penumbra director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 08:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grewal Harpreet

(Last) (First) (Middle)

ONE PENUMBRA PLACE

(Street)

ALAMEDA CA 94502

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Penumbra Inc [ PEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		A		589(1)	A	$0	8,819(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units (RSUs) vest as to 1/4 on each of March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to Mr. Grewal's continued service as director through such dates. Notwithstanding the foregoing, if the Closing (as defined in that certain Agreement and Plan of Merger, dated as of January 14, 2026, among the Issuer, Boston Scientific Corporation, a Delaware corporation, and Pinehurst Merger Sub, Inc., a Delaware corporation) occurs, any of the RSUs that remain unvested will fully vest on the Closing, subject to Mr. Grewal's continued service as director through such date.

2. A portion of these shares is subject to vesting.

Remarks:

	/s/ Johanna Roberts, as attorney-in-fact for Harpreet Grewal	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.